Today (11/5) Merck announced their all-cash acquisition of San Diego’s VelosBio following the release of Phase 1 data of ROR1 targeting VLS-101. VLS-101 is a drug for treatment of hematologic malignancies, and exited clinical trial Phase 1 with results showing complete responses in 47% of patients with mantle-cell lymphoma and 80% of patients with diffuse large B-cell lymphoma. VelosBio has initiated a Phase two clinical trial for VLS-101 on patients with solid tumors and expects to develop their cancer pipeline with alternative tumor cell-killing methods.

Learn more here.

More on: